Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis
Geraldine Siegfried, … , Nabil G. Seidah, Abdel-Majid Khatib
Geraldine Siegfried, … , Nabil G. Seidah, Abdel-Majid Khatib
Published June 1, 2003
Citation Information: J Clin Invest. 2003;111(11):1723-1732. https://doi.org/10.1172/JCI17220.
View: Text | PDF
Article Oncology

The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis

  • Text
  • PDF
Abstract

The secretory factor VEGF-C has been directly implicated in various physiological processes during embryogenesis and human cancers. However, the importance of the conversion of its precursor proVEGF-C to mature VEGF-C in tumorigenesis, and vessel formation and the identity of the protease(s) that regulate these processes is/are not known. The intracellular processing of proVEGF-C that occurs within the dibasic motif HSIIRR227SL suggests the involvement of the proprotein convertases (PCs) in this process. In addition, furin and VEGF-C were found to be coordinately expressed in adult mouse tissues. Cotransfection of the furin-deficient colon carcinoma cell line LoVo with proVEGF-C and different PC members revealed that furin, PC5, and PC7 are candidate VEGF-C convertases. This finding is consistent with the in vitro digestions of an internally quenched synthetic fluorogenic peptide mimicking the cleavage site of proVEGF-C (220Q-VHSIIRR↓SLP230). The processing of proVEGF-C is blocked by the inhibitory prosegments of furin, PC5, and PACE4, as well as by furin-motif variants of α2-macroglobulin and α1-antitrypsin. Subcutaneous injection of CHO cells stably expressing VEGF-C into nude mice enhanced angiogenesis and lymphangiogenesis, but not tumor growth. In contrast, expression of proVEGF-C obtained following mutation of the cleavage site (HSIIRR227SL to HSIISS227SL) inhibits angiogenesis and lymphangiogenesis as well as tumor growth. Our findings demonstrate the processing of proVEGF-C by PCs and highlight the potential use of PC inhibitors as agents for inhibiting malignancies induced by VEGF-C.

Authors

Geraldine Siegfried, Ajoy Basak, James A. Cromlish, Suzanne Benjannet, Jadwiga Marcinkiewicz, Michel Chrétien, Nabil G. Seidah, Abdel-Majid Khatib

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Processing of proVEGF-C by furin, PC5, and PC7. (a) Schematic representa...
Processing of proVEGF-C by furin, PC5, and PC7. (a) Schematic representation of the primary structure of the 419-AA human proVEGF-C. Shown are the signal peptide (SP), PC-processing site (HSIIRR227SL), an unknown protease site (indicated by question mark) that generates the 21-kDa VEGF-C, and the Flag attached to the C-terminus. ProVEGF-C processing was analyzed by biosynthesis (b) and Western blotting (c) of LoVo-C5–conditioned media obtained from cells transiently transfected with either the empty vectors (None), pIRES2-EGFP vector and pcDNA3-zeo-Flag.cm5 vector containing proVEGF-C (Control), or with the pcDNA3-zeo-Flag.cm5 vector containing proVEGF-C and pIRES2-EGFP vector that expresses full-length human furin, PACE4, or SKI-1; mouse PC5A or PC5B; or rat PC7. The corresponding percentages of proVEGF-C cleavage calculated from the ratio of band intensities of VEGF-C/(proVEGF-C + VEGF-C) are indicated.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts